BioSpace News Archive

The pharma company will lay off 170 employees and drop all candidates but one, as it seeks to rebuild its business.

The delay and guidance downgrade follow a spate of operational issues that have affected three of Catalent’s major manufacturing sites.

Clinical lab techs are in high demand in healthcare, pharma and biotech. Here’s a look at what they do, career advancement opportunities within the role and the training required to become one.

The layoffs come as the company posts nearly $300 million in net losses and just over $80 million in revenue during the first quarter of 2023.

Humacyte, Inc. (Nasdaq: HUMA) today announced the publication in The Lancet Regional Health - Europe detailing the encouraging experience of Humacyte’s investigational Human Acellular Vessel (HAV) in treating battlefield and other vascular trauma injuries suffered in Ukraine-Russia conflict.

Replimune Group, Inc. announced that members from the Replimune management team will host investor meetings at the Piper Sandler Spring Biopharma Symposium being held from Wednesday, May 17 through Thursday, May 18, 2023 at the Encore Boston Harbor in Boston, MA.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.

Omeq Medical Ltd. a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), announced today that it has received regulatory clearance from the United States Food and Drug Administration (“FDA”) for its EpiFinder, which assists physicians to accurately position an epidural needle while performing the standard Loss of Resistance (“LOR”) technique.

Delix Therapeutics (the “Company”), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the regulatory approval and initiation of recruitment of a phase I clinical trial of lead candidate, DLX-001, a non-hallucinogenic psychoplastogen.

Ratio Therapeutics Inc. is pleased to announce the opening of its new 19,000-square-foot headquarters and R&D facility in the famous Innovation and Design Building located in Boston’s Seaport District.